百利天恒通过联交所聆讯

Core Insights - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has submitted its prospectus on September 29 and passed the hearing at the Hong Kong Stock Exchange on October 21 [2] - The company focuses on the global frontier of biomedicine, aiming to address unmet clinical needs, particularly in the field of tumor macromolecule therapy, and possesses leading innovative R&D capabilities [2] - The company plans to establish comprehensive global commercialization capabilities by 2029 [2] Financial Performance - The net profit for the fiscal year 2023 is projected to be -780 million yuan, representing a year-on-year change of -176.40% [2] - For the fiscal year 2024, the net profit is expected to reach 3.708 billion yuan, with a significant year-on-year increase of 575.02% [2] - The net profit for the first half of 2025, as of June 30, is forecasted to be -1.118 billion yuan, reflecting a year-on-year change of -123.96% [2]